Dokter terbaik untuk pengobatan Kanker nasofaring di luar negeri — Halaman 2

Dokter adalah seorang ahli onkologi yang sangat dihormati di Anadolu Medical Center, yang berspesialisasi dalam onkologi medis dan kemoterapi. Setelah memperoleh gelar kedokteran dari Universitas Ankara pada tahun 2005, dokter menyelesaikan pelatihan spesialisasi dalam bidang penyakit dalam di Universitas Istanbul dan lebih lanjut berspesialisasi dalam onkologi medis di Universitas Marmara pada tahun 2017. Dokter telah memimpin unit onkologi medis di Rumah Sakit Pelatihan dan Penelitian Haydarpaşa Numune dan telah berpartisipasi dalam banyak studi klinis internasional. Dokter berfokus pada berbagai jenis kanker, termasuk kanker payudara, urologi, paru-paru, dan kanker gastrointestinal, di antara lainnya.<\/p>

Dokter adalah anggota dari beberapa masyarakat onkologi bergengsi, termasuk Masyarakat Onkologi Medis Turki, Masyarakat Onkologi Medis Eropa, dan Masyarakat Onkologi Medis Amerika. Dokter telah berpartisipasi dalam program pelatihan lanjutan secara global, termasuk program di Universitas Oxford dan ESMO.<\/p>

Dr. Mehmet Dogu Canoglu adalah ahli onkologi radiasi di Anadolu Medical Center di Istanbul. Beliau berspesialisasi dalam penargetan tumor secara presisi menggunakan teknologi MR Linac dan CyberKnife. Dr. Canoglu menempuh pendidikan di Universitas Kocaeli. Sebelumnya, beliau bertugas di Rumah Sakit Universitas Medipol Mega. Beliau menangani berbagai jenis kanker, termasuk tumor otak, prostat, dan paru-paru yang kompleks.

• Pakar dalam sistem pengiriman radiasi Varian TrueBeam dan Trilogy.
• Melakukan bedah radio stereotaksis dan radioterapi terarah untuk sarkoma.
• Bekerja di Anadolu Medical Center, fasilitas yang berafiliasi dengan Johns Hopkins Medicine.
• Menangani pasien di klinik yang masuk dalam peringkat 10 besar dunia untuk wisata medis.

Dokter lulus dari Fakultas Kedokteran Universitas Ankara dan menyelesaikan pelatihan residensi dalam bidang penyakit dalam di Fakultas Kedokteran GATA Ankara. Mengkhususkan diri dalam onkologi medis dan hematologi, dokter menyelesaikan fellowship klinis di AS. Sebagai pelopor di Turki, dokter adalah bagian dari tim yang melakukan transplantasi sumsum tulang pertama di negara tersebut. Dokter telah menjadi dosen tamu di lembaga-lembaga bergengsi di London dan Swiss. Memegang Sertifikat Onkologi Medis Eropa, dokter adalah anggota pendiri dari baik Masyarakat Onkologi Medis Turki maupun Kelompok Onkologi Turki. Fokus klinis termasuk kanker payudara, gastrointestinal, paru-paru, limfoma, dan mieloma.<\/p>

Profesor dengan 15+ tahun pengalaman spesialisasi dalam kanker gastrointestinal dan nasofaring di Rumah Sakit Gayrettepe Florence Nightingale.

• Fellowship onkologi medis dari Universitas Istanbul
• Anggota ESMO, ASCO, dan European Neuroendocrine Tumor Society
• Memimpin Departemen Onkologi Medis di rumah sakit terkemuka di Istanbul

Prof. Köstler adalah ahli onkologi medis terkemuka di Wiener Privatklinik Wina yang bergengsi, dengan spesialisasi dalam terapi target dan imunoterapi tingkat lanjut.

• Lebih dari _doctor_1748_tahun_ pengalaman sebagai ahli onkologi dan internis
• Berfokus pada keganasan payudara dan ginekologi
• Profesor asosiasi di Universitas Kedokteran Wina
• Mempublikasikan penelitian tentang pengembangan biomarker dan biologi tumor
• Pakar dalam merancang rencana terapi kanker sistemik yang dipersonalisasi

Lebih dari 1.100 perawatan kanker dilakukan – Dr. Ozadli berspesialisasi dalam kanker nasofaring di Valued Med Hub Hospitals sebagai asisten profesor.

• _doctor_5177_tahun_ pengalaman dalam onkologi medis
• Terlatih di Rumah Sakit Pelatihan dan Penelitian Onkologi Ankara
• Pakar dalam kanker paru-paru, kerongkongan, lambung, dan payudara
• Peneliti aktif dengan publikasi di bidang onkologi

Dr. Orit Gutfeld adalah ahli onkologi yang berspesialisasi dalam kanker THT, dengan pengalaman klinis lebih dari _doctor_235_ tahun.

• Telah melakukan ribuan operasi untuk tumor kepala dan leher
• Berspesialisasi dalam teknik invasif minimal seperti bedah endoskopi
• Menggunakan bedah radio canggih, termasuk perawatan Gamma Knife
• Memimpin Divisi Onkologi Institut Radioterapi di Ichilov Medical Center
• Berpartisipasi dalam penelitian ilmiah dan uji klinis di Ichilov

Profesor Dan Fliss adalah seorang onkolog berpengalaman yang berspesialisasi dalam kanker nasofaring di Sourasky Medical Center (Ichilov).

• Berspesialisasi dalam menangani kasus kanker nasofaring yang kompleks
• Berafiliasi dengan salah satu pusat medis terkemuka di Israel
• Memegang gelar profesor di bidang onkologi

Dr. Fox memimpin pusat kanker bersertifikat di Solingen, yang berspesialisasi dalam kanker kepala dan leher termasuk kanker nasofaring.

• Lebih dari _doctor_6587_tahun_ pengalaman dalam hematologi dan onkologi
• Pakar dalam diagnostik molekuler dan terapi target
• Secara aktif meneliti perawatan baru untuk penyakit hemato-onkologi
• Anggota American Association for Cancer Research

Dr. Liu Shi Xin adalah Wakil Ketua Cabang Onkologi Radiasi dari Asosiasi Medis Tiongkok. Beliau menjabat sebagai Pemimpin Disiplin Pusat Onkologi di Rumah Sakit Xiamen Humanity. Dr. Liu berspesialisasi dalam radioterapi presisi untuk kanker toraks dan abdomen. Beliau adalah penerima Tunjangan Pemerintah Khusus Dewan Negara atas kontribusi medisnya.

• Sangat mahir dalam IMRT, VMAT, dan SBRT untuk kanker paru-paru dan esofagus.
• Mantan Presiden Rumah Sakit Kanker Provinsi Jilin.
• Dianugerahi gelar Dokter Terkenal Nasional atas kontribusi luar biasa dalam onkologi.
• Memegang peran kepemimpinan dalam komite terapi partikel Asosiasi Anti-Kanker Tiongkok.

Profesor Keil berspesialisasi dalam radiologi diagnostik dan intervensi, menerapkan teknik pencitraan canggih seperti MRI dan CT di Rumah Sakit Akademik Solingen.

• Lulus dengan predikat kehormatan dari Universitas Julius-Maximilians Würzburg
• Memperdalam keahlian di bawah bimbingan profesor ternama Rolf W. Günther
• Dokter terkemuka sejak 2010 dalam Radiologi Diagnostik dan Intervensi
• Berspesialisasi dalam pencitraan penampang dan layanan radiologi intervensi

49 tahun berspesialisasi dalam viroterapi – Dr. Jaunalksne memimpin Pusat Imunologi Klinis di Rumah Sakit Universitas Klinis Pauls Stradins.

• Lulusan Institut Medis Riga
• Magang di Penyakit Dalam
• Kepala Pusat Imunologi Klinis

Dr. Mariam Abu Zeid adalah onkolog klinis di Shefaa Al Orman International Oncology Hospitals. Beliau bersertifikat dari European Society for Medical Oncology (ESMO). Dr. Abu Zeid menangani tumor padat dan kanker hematologi. Beliau memegang gelar Ph.D. dalam Onkologi Klinis dan Kedokteran Nuklir dari Universitas Ain Shams.

• Memberikan kemoterapi, imunoterapi, dan perawatan terarah untuk berbagai jenis kanker.
• Mengawasi uji klinis onkologi dan mengelola toksisitas terkait pengobatan.
• Mengoordinasikan perawatan pasien dalam tim multidisiplin untuk penentuan stadium dan diagnosis yang kompleks.
• Berpraktik di pusat yang terakreditasi ESMO yang menangani sekitar 6.000 pasien setiap tahunnya.

Spesialis onkologi medis dengan pelatihan ekstensif di Universitas Akdeniz – salah satu sekolah kedokteran terkemuka di Turki.

• Bersertifikat dalam onkologi medis sejak 2018
• Lebih dari _doctor_9570_ tahun pengalaman dalam penyakit dalam dan onkologi
• Pernah bekerja di berbagai rumah sakit universitas termasuk Rumah Sakit Universitas Akdeniz
• Anggota Asosiasi Onkologi Medis Turki

Dr. Ozden membawa pengalaman lebih dari satu dekade dalam onkologi medis khusus untuk kasus kanker nasofaring. Beliau menempuh pendidikan di Fakultas Kedokteran Cerrahpaşa yang bergengsi di Universitas Istanbul.

• Menyelesaikan subspesialisasi onkologi medis di Universitas Kocaeli
• Berpraktik di bidang penyakit dalam dan onkologi sejak 2004
• Latar belakang pendidikan kedokteran dalam bahasa Inggris
• Bekerja di Rumah Sakit VM Medical Park Pendik

Dr. Muhammed Mustafa Atci adalah Profesor Madya Onkologi Medis di Liv Hospital Topkapı. Beliau berspesialisasi dalam pengobatan kanker usus besar, payudara, lambung, dan paru-paru. Sebelumnya, beliau menjabat sebagai Koordinator Pendidikan di Rumah Sakit Kota Prof. Dr. Cemil Taşcıoğlu. Dr. Atci adalah anggota American Society of Clinical Oncology (ASCO).

• Penulis 19 makalah yang ditinjau sejawat tentang kanker gastrointestinal, toraks, dan endokrin.
• Menerbitkan studi tentang hasil kelangsungan hidup untuk kanker usus besar stadium IIB di Journal of Chemotherapy.
• Meneliti biomarker prognostik menggunakan pemindaian PET/CT dan volume tumor metabolik.
• Menangani kasus onkologi kompleks di klinik universitas İstinye University.

Dr. Irfan Cicin adalah Profesor Onkologi Medis di Rumah Sakit İstinye University Liv Topkapı. Beliau berspesialisasi dalam menangani kanker kompleks, termasuk glioblastoma, kanker paru-paru, dan tumor pankreas. Beliau menjabat sebagai profesor di Fakultas Kedokteran Universitas Trakya. Dr. Cicin sebelumnya pernah bertugas sebagai dokter di Angkatan Udara Turki.

• Melakukan terapi sistemik seperti imunoterapi, kemoterapi, dan terapi hormon.
• Menangani berbagai kondisi termasuk kasus ginekologi, ortopedi, dan neuro-onkologi.
• Pakar dalam HIPEC dan kemoembolisasi untuk keganasan hati dan perut.
• Bekerja di rumah sakit universitas dengan 300 tempat tidur dan 33 departemen medis.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Raanan Berger adalah Direktur Pusat Kanker di Sheba Medical Center. Beliau masuk dalam daftar "Dokter Terbaik" Forbes Israel pada tahun 2025. Dr. Berger berspesialisasi dalam onkologi genitourinari dan melakukan radioterapi pada tumor prostat yang kompleks. Beliau menyelesaikan fellowship pascadoktoral di Dana-Farber/Harvard Cancer Institute.

• Memimpin unit penelitian klinis yang berfokus pada onkologi molekuler.
• Penulis bersama lebih dari 20 makalah yang ditinjau sejawat tentang kanker prostat dan mutasi BRCA.
• Anggota American Society of Clinical Oncology (ASCO).
• Melakukan terapi sistemik dan radioterapi di rumah sakit yang masuk dalam peringkat 10 besar dunia.